- Home
- NTRA vs ONC Comparison
NTRA vs ONC Comparison
Compare NTRA & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTRA
- ONC
- Stock Information
- Founded
- NTRA 2003
- ONC 2010
- Country
- NTRA United States
- ONC Cayman Islands
- Employees
- NTRA N/A
- ONC N/A
- Industry
- NTRA Medical Specialities
- ONC Biotechnology: Pharmaceutical Preparations
- Sector
- NTRA Health Care
- ONC Health Care
- Exchange
- NTRA Nasdaq
- ONC Nasdaq
- Market Cap
- NTRA 18.4B
- ONC 19.3B
- IPO Year
- NTRA 2015
- ONC N/A
- Fundamental
- Price
- NTRA $143.94
- ONC $267.39
- Analyst Decision
- NTRA Strong Buy
- ONC Buy
- Analyst Count
- NTRA 17
- ONC 2
- Target Price
- NTRA $179.00
- ONC $330.50
- AVG Volume (30 Days)
- NTRA 1.9M
- ONC 490.8K
- Earning Date
- NTRA 05-08-2025
- ONC 05-07-2025
- Dividend Yield
- NTRA N/A
- ONC N/A
- EPS Growth
- NTRA N/A
- ONC N/A
- EPS
- NTRA N/A
- ONC N/A
- Revenue
- NTRA $1,696,911,000.00
- ONC $3,810,241,000.00
- Revenue This Year
- NTRA $13.56
- ONC $856.26
- Revenue Next Year
- NTRA $18.11
- ONC $19.78
- P/E Ratio
- NTRA N/A
- ONC N/A
- Revenue Growth
- NTRA 56.75
- ONC 54.97
- 52 Week Low
- NTRA $83.13
- ONC $126.97
- 52 Week High
- NTRA $183.00
- ONC $287.88
- Technical
- Relative Strength Index (RSI)
- NTRA 41.35
- ONC N/A
- Support Level
- NTRA $146.35
- ONC N/A
- Resistance Level
- NTRA $155.64
- ONC N/A
- Average True Range (ATR)
- NTRA 6.42
- ONC 0.00
- MACD
- NTRA 0.87
- ONC 0.00
- Stochastic Oscillator
- NTRA 51.93
- ONC 0.00
About NTRA Natera Inc.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.